Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 12 - 22 save search
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $98.35 1.1% 0.32% 5.9K
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
ALNY | $143.8 -1.55% -1.58% 50
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
leqvio fda fda approval approval
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $98.35 1.1% 0.32% 5.9K
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
leqvio novartis fda cholesterol
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Published: 2021-12-22 (Crawled : 22:00) - arcutis.com
ARQT | $8.75 0.11% 0.23% 230
|
Health Technology
|
| O: 1.67%
H: 8.12%
C: 6.63%
new drug fda application drug therapeutics psoriasis iot fda acceptance plague
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Published: 2021-12-22 (Crawled : 20:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.38% 130K
|
Health Technology
|
| O: 0.51%
H: 2.25%
C: 0.51%
covid-19 treatment fda covid authorization antiviral merge emergency use authorization
Takeda Stumbles to be First EoE Treatment to Market Following FDA CRL
Published: 2021-12-22 (Crawled : 19:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
treatment fda
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2021-12-22 (Crawled : 15:00) - biospace.com/
JAGX | News | $0.1699 1.13% 1.41% 1.5M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Published: 2021-12-22 (Crawled : 14:00) - biospace.com/
ALLR | $1.37 -3.52% -3.65% 4K
|
n/a
|
| O: 4.76%
H: 35.91%
C: 14.77%
new drug treatment fda application renal drug therapeutics cel cell carcinoma
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
Published: 2021-12-22 (Crawled : 14:00) - biospace.com/
SGHT | $5.62 -0.36% 0.0% 0
|
|
| O: 0.48%
H: 1.62%
C: -3.82%
tearcare dry eye treatment fda clearance eye eye disease disease
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
Published: 2021-12-21 (Crawled : 01:00) - globenewswire.com
CERT | $16.45 -1.67% -1.79% 10
|
|
| O: 1.27%
H: 3.34%
C: 2.58%
fda expansion software submission
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
OPTN | $0.9253 -4.38% 30.38% 5.3M
|
Health Services
SGBX | $0.1441 -2.24% 29.47% 6.1M
|
Producer Manufacturing
PCSA | $1.62 1.25% 21.95% 7.1M
|
Producer Manufacturing
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
SPCB | News 4 d | $0.2236 -6.83% 12.09% 20M
|
Electronic Technology
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
OMQS | $0.411 -2.81% 9.83% 1.2M
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.